Pfizer has long been a partner in the global effort to eliminate trachoma, the world’s leading infectious cause of blindness, through its donation of an oral antibiotic that can help treat and prevent the debilitating disease. Now, Pfizer has announced that it will extend its donation of the antibiotic through 2025, building on the company’s 20-year support of a partnership to eliminate this disease.
When Dr. Charles A. Knirsch, MD, MPH, joined Pfizer more than 20 years ago, planning had just begun for a new partnership to eliminate trachoma, a neglected tropical disease and the world’s leading infectious cause of blindness.
The New England Journal of Medicine has published results from a new study showing that the use of an antibiotic significantly reduced mortality among children living in three low-income countries in Sub-Saharan Africa.
Novartis has received approval for its new powdered formulation for an inhaled cystic fibrosis therapy. The inhaled antibiotic was recommended to regulators for approval by an FDA advisory panel. Novartis’s previous delivery system earned sales of $300 million dollars last year.